Adrenalectomy improves arterial stiffness in primary aldosteronism

American Journal of Hypertension

Volumn 21, Issue 10, 2008, Pages 1086-1092

  Štrauch, Branislav ^a   Petrák, Ondřej ^a   Zelinka, Tomáš ^a   Wichterle, Dan ^b   Holaj, Robert ^a   Kasalický, Mojmír ^a   Šafařík, Libor ^a   Rosa, Ján ^a   Widimský Jr , Jiří ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

^b INSTITUTE FOR CLINICAL AND EXPERIMENTAL MEDICINE   (Czech Republic)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE; AMILORIDE; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DOXAZOSIN; HYDROCHLOROTHIAZIDE; RENIN; SPIRONOLACTONE; VERAPAMIL;

ADENOMA; ADRENALECTOMY; ADULT; ALDOSTERONE BLOOD LEVEL; ARTERIAL STIFFNESS; ARTICLE; AUGMENTATION INDEX; BLOOD PRESSURE MONITORING; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; DRUG DOSE TITRATION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; GYNECOMASTIA; HEART RATE; HUMAN; HYPERTENSION; IDIOPATHIC DISEASE; LAPAROSCOPIC SURGERY; MALE; MENSTRUAL IRREGULARITY; PLASMA RENIN ACTIVITY; PRIMARY HYPERALDOSTERONISM; PRIORITY JOURNAL; PULSE PRESSURE; PULSE WAVE; TONOMETER;

ADRENALECTOMY; ALDOSTERONE; BLOOD PRESSURE; CAROTID ARTERIES; FEMALE; FEMORAL ARTERY; FOLLOW-UP STUDIES; HUMANS; HYPERALDOSTERONISM; LAPAROSCOPY; MALE; MIDDLE AGED; RADIOIMMUNOASSAY; RENIN; TREATMENT OUTCOME; VASCULAR RESISTANCE;

EID: 52449098944     PISSN: 08957061     EISSN: None     Source Type: Journal    
DOI: 10.1038/ajh.2008.243     Document Type: Article

References (37)

1. Stowasser M. Primary aldosteronism: revival of a syndrome. J Hypertens 2001; 19:363-366.
2. Rossi GP, Bernini G, Caliumi C, Desideri G, Fabris B, Ferri C, Ganzaroli C, Giacchetti G, Letizia C, Maccario M, Mallamaci F, Mannelli M, Mattarello MJ, Moretti A, Palumbo G, Parenti G, Porteri E, Semplicini A, Rizzoni D, Rossi E, Boscaro M, Pessina AC, Mantero F. PAPY Study Investigators. A prospective study of the prevalence of primary aldosteronism in 1,125 hypertensive patients. J Am Coll Cardiol 2006; 48:2293-2300.
3. Štrauch B, Zelinka T, Hampf M, Bernhardt R, Widimský J Jr. Prevalence of primary hyperaldosteronism in moderate to severe hypertension in the Central Europe region. J Hum Hypertens 2003; 17:349-352.
4. Milliez P, Girerd X, Plouin PF, Blacher J, Safar ME, Mourad JJ. Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J Am Coll Cardiol 2005; 45:1243-1248.
5. Catena C, Colussi G, Nadalini E, Chiuch A, Baroselli S, Lapenna R, Sechi LA. Cardiovascular outcomes in patients with primary aldosteronism after treatment. Arch Intern Med 2008; 168:80-85.
6. Rossi GP, Sacchetto A, Visentin P, Canali C, Graniero GR, Palatini P, Pessina AC. Changes in left ventricular anatomy and function in hypertension and primary aldosteronism. Hypertension 1996; 27:1039-1045.
7. Rossi GP, Bernini G, Desideri G, Fabris B, Ferri C, Giacchetti G, Letizia C, Maccario M, Mannelli M, Matterello MJ, Montemurro D, Palumbo G, Rizzoni D, Rossi E, Pessina AC, Mantero F. PAPY Study Participants. Renal damage in primary aldosteronism: results of the PAPY Study. Hypertension 2006; 48:232-238.
8. Holaj R, Zelinka T, Wichterle D, Petrák O, Štrauch B, Widimský J Jr. Increased intima-media thickness of the common carotid artery in primary aldosteronism in comparison with essential hypertension. J Hypertens 2007; 25:1451-1457. Erratum in: J Hypertens 2007; 25:1749.
9. Zelinka T, Strauch B, Pecen L, Widimský J Jr. Diurnal blood pressure variation in pheochromocytoma, primary aldosteronism and Cushing's syndrome. J Hum Hypertens. 2004; 18:107-111.
10. Brown NJ. Aldosterone and end-organ damage. Curr Opin Nephrol Hypertens 2005; 14:235-241.
11. Fuller PJ, Young MJ. Mechanisms of mineralocorticoid action. Hypertension 2005; 46:1227-1235.
12. Benetos A, Lacolley P, Safar ME. Prevention of aortic fibrosis by spironolactone in spontaneously hypertensive rats (SHRs). Arterioscler Thromb Vasc Biol 1997; 17:1152-1156.
13. Lacolley P, Labat C, Pujol A, Delcayre C, Benetos A, Safar M. Increased carotid wall elastic modulus and fibronectin in aldosterone-salt treated rats - effects of eplerenone. Circulation 2002; 106:2848-2853.
14. Nehme J, Mercier N, Labat C, Benetos A, Safar ME, Delcayre C, Lacolley P. Differences between cardiac and arterial fibrosis and stiffness in aldosterone-salt rats: effect of eplerenone. J Renin Angiotensin Aldosterone Syst 2006; 7:31-39.
15. Joffe HV, Adler GK. Effect of aldosterone and mineralocorticoid receptor blockade on vascular inflammation. Heart Fail Rev 2005; 10:31-37.
16. Mahmud A, Feely J. Aldosterone-to-renin ratio, arterial stiffness, and the response to aldosterone antagonism in essential hypertension. Am J Hypertens 2005; 18:50-55.
17. Rizzoni D, Paiardi S, Rodella L, Porteri E, De Ciuceis C, Rezzani R, Boari GE, Zani F, Miclini M, Tiberio GA, Giulini SM, Rosei CA, Bianchi R, Rosei EA. Changes in extracellular matrix in subcutaneous small resistance arteries of patients with primary aldosteronism. J Clin Endocrinol Metab 2006; 91:2638-2642.
18. Štrauch B, Petrák O, Wichterle D, Zelinka T, Holaj R, Widimský J Jr. Increased arterial wall stiffness in primary aldosteronism in comparison with essential hypertension. Am J Hypertens 2006; 19:909-914.
19. Rossi GP, Belfiore A, Bernini G, Desideri G, Fabris B, Ferri C, Giacchetti G, Letizia C, Maccario M, Mallamaci F, Mannelli M, Montemurro D, Palumbo G, Rizzoni D, Rossi E, Semplicini A, Agabiti-Rosei E, Pessina AC, Mantero F. PAPY Study Investigators. Prospective evaluation of the saline infusion test for excluding primary aldosteronism due to aldosterone-producing adenoma. J Hypertens 2007; 25:1433-1442.
20. Giacchetti G, Ronconi V, Lucarelli G, Boscaro M, Mantero F. Analysis of screening and confirmatory tests in the diagnosis of primary aldosteronism: need for a standardized protocol. J Hypertens 2006; 24:737-745.
21. Mulatero P, Stowasser M, Loh KC, Fardella CE, Gordon RD, Mosso L, Gomez-Sanchez CE, Veglio F, Young WF Jr. Increased diagnosis of primary aldosteronism, including surgically correctable forms, in centers from five continents. J Clin Endocrinol Metab 2004; 89:1045-1050.
22. O'Rourke MF, Pauca A, Jiang X-J. Pulse wave analysis. Br J Clin Pharmacol 2001; 51:507-522.
23. Pauca AL, O'Rourke MF, Kon ND. Prospective evaluation of a method for estimating ascending aortic pressure from the radial artery pressure waveform. Hypertension 2001; 38:932-937.
24. Siebenhofer A, Kemp CRW, Sutton AJ, Williams B. The reproducibility of central aortic blood pressure measurements in healthy subjects using applanation tonometry and sphygmocardiography. J Hum Hypertens 1999; 13:625-629.
25. Filipovsky J, Svobodova V, Pecen L. Reproducibility of radial pulse wave analysis in healthy subjects. J Hypertens 2000; 18:1033-1040.
26. Avolio AP, Deng Fq, Li WQ, Luo YF, Huang ZD, Xing LF, O'Rourke MF. Effects of aging on arterial distensibility in populations with high and low prevalence of hypertension: comparison between urban and rural communities in China. Circulation 1985; 71:202-210
27. Safar ME, Rourke MF. Arterial stiffness in hypertension. In Birkenhager WH, Reid JL (eds). Handbook of Hypertension, Vol 23. Elsevier: Amsterdam, 2006, 568-570.
28. Jeunemaitre X, Chatellier G, Kreft-Jais C, Charru A, DeVries C, Plouin PF, Corvol P, Menard J. Efficacy and tolerance of spironolactone in essential hypertension. Am J Cardiol 1987; 60:820-825.
29. Mulatero P, Bertello C, Rossato D, Mengozzi G, Milan A, Garrone C, Giraudo G, Passarino G, Garabello D, Verhovez A, Rabbia F, Veglio F. Roles of clinical criteria, computed tomography scan, and adrenal vein sampling in differential diagnosis of primary aldosteronism subtypes. J Clin Endocrinol Metab 2008; 93:1366-1371.
30. Christ M, Douwes K, Eisen C, Bechtner G, Theisen K, Wehling M. Rapid effects of aldosterone on sodium transport in vascular smooth muscle cells. Hypertension 1995; 25:117-123.
31. +-adenosine triphosphatase in arterial vessels. Endocrinology 2003; 144:1266-1272.
32. Romagni P, Rossi F, Guerrini L, Quirini C, Santiemma V. Aldosterone induces contraction of the resistance arteries in man. Atherosclerosis 2003; 166:345-349.
33. Catena C, Colussi G, Lapenna R, Nadalini E, Chiuch A, Gianfagna P, Sechi LA. Long-term cardiac effects of adrenalectomy or mineralocorticoid antagonists in patients with primary aldosteronism. Hypertension 2007; 50:911-918.
34. Duprez DA, De Buyzere ML, Rietzschel ER, Taes Y, Clement DL, Morgan D, Cohn JN. Inverse relationship between aldosterone and large artery compliance in chronically treated heart failure patients. Eur Heart J 1998; 19:1371-1376.
35. Lijnen P, Petrov V. Induction of cardiac fibrosis by aldosterone. J Moll Cell Cardiol 2000; 32:865-879.
36. Rossi GP, Bolognesi M, Rizzoni D, Seccia TM, Piva A, Porteri E, Tiberio GA, Giulini SM, Agabiti-Rosei E, Pessina AC. Vascular remodeling and duration of hypertension predict outcome of adrenalectomy in primary aldosteronism patients. Hypertension 2008; 51:1366-1371.
37. Rossi GP, Belfiore A, Bernini G, Desideri G, Fabris B, Ferri C, Giacchetti G, Letizia C, Maccario M, Mallamaci F, Mannelli M, Palumbo G, Rizzoni D, Rossi E, Agabiti-Rosei E, Pessina AC, Mantero F. Primary Aldosteronism Prevalence in Italy Study Investigators. Comparison of the captopril and the saline infusion test for excluding aldosterone-producing adenoma. Hypertension 2007; 50:424-431.